Interesting ImagesRecurrent Brain Metastasis of Triple Negative Breast Cancer With High Uptake in 68Ga-PSMA-11 PET/CTArslan, Esra MD∗; Ergül, Nurhan MD∗; Karagöz, Yeşim MD†; Gedik, Arzu Algün MD‡; Çermik, Tevfik Fikret MD∗Author Information From the Departments of ∗Nuclear Medicine †Radiology ‡Pathology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. Received for publication May 22, 2020; revision accepted August 31, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Esra Arslan, MD, Istanbul Egitim ve Arastırma Hastanesi, Nukleer Tıp Kliniği, Org. Nafiz Gurman Caddesi, 34098 Samatya, Kocamustafapasa, Fatih, Istanbul, Turkey. E-mail: [email protected]. Clinical Nuclear Medicine: February 2021 - Volume 46 - Issue 2 - p e106-e108 doi: 10.1097/RLU.0000000000003336 Buy Metrics Abstract Triple negative breast cancer (TNBC) is characterized by poor prognosis and limited response to standard treatments. Although 18F-FDG PET/CT is frequently used in staging and restaging, in some cases, it may be insufficient considering tumor heterogeneity. Prostate-specific membrane antigen (PSMA) has been reported to be overexpressed in many types of cancer due to tumor-associated neovascularization. 68Ga-PSMA-11 PET/CT can be used to demonstrate radionuclide therapy option as well as detection of primary tumor and recurrence in TNBC. We present a 47-year-old woman with TNBC having recurrent brain metastasis with avid PSMA receptor activity versus low FDG uptake. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.